Olaplex (OLPX) Q4 2024 earnings summary

Executive summary

• 2024 was a year of transformation, with strategic focus on innovation, marketing, operational excellence, and key leadership hires to support future growth.

• Q4 2024 net sales declined 9.8% year-over-year to $100.7M, with FY 2024 net sales at $422.7M, and net income turning negative.

• Adjusted EBITDA for FY 2024 was $129.7M (30.7% margin); Q4 adjusted EBITDA was $17.5M (17.4% margin).

• The new 'Bonds and Beyond' vision and expanded R&D capabilities aim to position the company as a foundational health and beauty leader.

• Transformation priorities included maximizing sales, marketing, and education investments, and developing a long-term roadmap.

Financial highlights

• Q4 2024 net sales: $100.7M, down 9.8% year-over-year; FY 2024 net sales: $422.7M, down 7.8%.

• Q4 adjusted EBITDA: $17.5M (17.4% margin), down from $36.0M (32.2%) in Q4 2023; FY 2024 adjusted EBITDA: $129.7M (30.7% margin).

• Q4 adjusted gross margin: 68.6%, down from 70.6% prior year, impacted by higher promotions and warehousing costs.

• Year-end cash and equivalents rose to $586M, up from $466.4M, with inventory reduced to $75.2M from $95.9M.

• Q4 adjusted net income was $7.6M; Q4 diluted EPS was $(0.01); adjusted diluted EPS $0.01.

Outlook and guidance

• FY 2025 net sales expected between $410M and $431M, representing -3% to +2% change from FY 2024.

• Adjusted gross margin projected at 70.5%-71.5%; adjusted EBITDA margin at 20%-22% for 2025.

• Q1 2025 net sales anticipated to be below full-year run rate, with demand growth expected as investments take effect.

• Continued investment in talent, R&D, and marketing, especially in the U.S., to drive transformation and innovation.